extrem investor pessim creat bar
upgrad gilead earli felt quarter earli
inde thesi mostli play total return incl dividend ytd
sub-optimal vs nbi investor concern fall three main categori
inhibitor filgotinib differenti approv
class-wid safeti black box sale moribund strong
biktarvi off-set truvada patent loss weak yescarta hcv sale
continu street seem expect bd deal soon last
two deal kite galapago inspir confid believ extrem
pessim set well stay bullish
filgotinib file ra prioriti review voucher month
review conduct extens due dilig finch phase
studi spoken opinion leader kol ra space attend
medic confer filgotinib data present debat
dilig continu see filgotinib best-in-class
filgotinib potenti domin ra pipelin indic
possibl creat anoth growth pillar numer exampl
late-market entrant achiev domin due better product profil
eylea tecfidera etc concern around vte venou
thromboembol and/or pe pulmonari embol legitim
believea kolsthat overst
term sales/earn concern point begin
consensu bloomberg expect year sinc
consensu expect increas close
street high expect continu strong convict
street high sales/earn expect
convict due hiv continu drive sales/earn growth
fast descovi prep uptak better product profil vs truvada eu hiv
return growth gener slowdown yescarta sale start
acceler reliabl due better reimburs coverag hcv
sale flatten market settl duopoli structur
regard bd/m remain sanguin investor desir
buy someth anyth other pooh-pooh recent deal believ
remain steadfast bring life-alt medicin market dividend
yield fcf/quarter non-gaap oper margin
see compani posit success spite current investor pessim
year price histori
gilead develop commerci
innov medicin area unmet
treatment hiv/aid liver diseas
cancer inflamm
analyst certif import disclosur see disclosur
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
rebound
believ addit savvi industri
veteran daniel day ceo announc year-
on-year sale growth import mid/late-stag clinic
readout bud franchis inflamm filgotinib
nash nash combin trial could start re-rat biotech
bellweth name among cheapest large-cap
phase studi data segatolimod hbv
submit descovi prep
complet list catalyst exhibit
hcv sale trough next two four quarter stable/up
patient diagnos treat
hiv busi outperform expect
yescarta us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
yescarta us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best
pt employ composit valuat methodolog biotechnolog compani util forward price-to-earnings multipl
npv adjust non-gaap estim earn sinc biotechnolog sector high-growth/high-expect rank target
compani base qualiti sale and/or earn growth versu peer group
peer index nbi index expect earn growth next three five year expect
appli lower termin multipl adj ep lower sales/earn growth trajectori vs peer
group appli discount rate gild valuat peer group averag
risk thesi includ follow
continu see sale declin margin deterior
mid/late-stag pipelin project inflamm filgotinib nash selonsertib combin trial nash unsuccess
new ceo oday abl execut acquisition/licens strategi help fundament strengthen faster expect
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax inc
capsid phase studi highli treatment experienc patient phase studi treatment-nav phase studyhematology/oncologyyescarta axicabtagen registr studi indol nhl phase combin studi atezolizumab data phase combin studi agonist enrol phase studi line high risk dlbcl phase phase studi cll potenti approv mcl file earli enrol phase studi mage solid clinic studi allogen totherremdesivir enrol phase studi ebola survivorsnash pbc psc updat phase studi diabet kidney fxr enrol phase studi phase studi hbvcombin data phase poc studi firsocostat cilofexor select phase studi phase studi ankylos enrol divers phase studi crohn phase studi cutan lupu phase studi sjogren syndrom data examin disclosur futur medic phase studi data phase studi ipf patient phase studi osteoarthr outperform
